Records 1 - 19
| Gene polymorphism of cytochrome P450 significantly affects lung cancer susceptibility.
Cancer medicine 2019 Jul .
Li Meng, Li Anqi, He Ruiqing, Dang Wenhui, Liu Xinyu, Yang Tian, Shi Puyu, Bu Xiang, Gao Dan, Zhang Ning, Du Shuli, Jin Tianbo, Chen Mingw
| Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers.
Journal of clinical pharmacology 2018 04 58 (4): 485-493.
Chen Yingxue, Zhou Diansong, Tang Weifeng, Zhou Wangda, Al-Huniti Nidal, Masson Er
| Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters.
Biological & pharmaceutical bulletin 2018 41 (1): 47-56.
Endo-Tsukude Chihiro, Sasaki Ji-Ichiro, Saeki Sho, Iwamoto Norihiro, Inaba Megumi, Ushijima Sunao, Kishi Hiroto, Fujii Shinji, Semba Hiroshi, Kashiwabara Kosuke, Tsubata Yukari, Hayashi Mitsuhiro, Kai Yuki, Saito Hideyuki, Isobe Takeshi, Kohrogi Hirotsugu, Hamada Akino
| Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2016 Mar 93 69-76.
Hirose Takashi, Fujita Ken-Ichi, Kusumoto Sojiro, Oki Yasunari, Murata Yasunori, Sugiyama Tomohide, Ishida Hiroo, Shirai Takao, Nakashima Masanao, Yamaoka Toshimitsu, Okuda Kentaro, Ohmori Tohru, Sasaki Yasutsu
| Interaction of the CYP1A1 gene polymorphism and smoking in non-small cell lung cancer susceptibility.
Genetics and molecular research : GMR 2016 14 (4): 19411-7.
Xie Y Q, Chen J M, Liu
| Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer.
Clinical lung cancer 2015 Jul 16 (4): 274-81.
Kobayashi Hiroyuki, Sato Kazuhiro, Niioka Takenori, Miura Hajime, Ito Hiroshi, Miura Masato
| Genetic polymorphisms of phase I and phase II metabolic enzymes as modulators of lung cancer susceptibility.
Journal of cancer research and clinical oncology 2015 May 141 (5): 851-60.
Mota P, Silva H C, Soares M J, Pego A, Loureiro M, Cordeiro C Robalo, Regateiro F
| Role of Metabolic Enzymes P450 (CYP) on Activating Procarcinogen and their Polymorphisms on the Risk of Cancers.
Current drug metabolism 2015 16 (10): 850-63.
He Xin, Feng Sh
| Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity.
Clinical lung cancer 2013 Sep 14 (5): 502-7.
Takimoto Takayuki, Kijima Takashi, Otani Yasushi, Nonen Shinpei, Namba Yoshinobu, Mori Masahide, Yokota Soichiro, Minami Seigo, Komuta Kiyoshi, Uchida Junji, Imamura Fumio, Furukawa Mitsugi, Tsuruta Naotoshi, Fujio Yasushi, Azuma Junichi, Tachibana Isao, Kumanogoh Atsus
| CYP2D6 T188C variant is associated with lung cancer risk in the Chinese population.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2013 Aug 34 (4): 2189-93.
Huang Yan, Liu Xin, Kuang Xin, Liao Duanfa
| CYP2A6, CYP1A1, and CYP2D6 polymorphisms in lung cancer patients from central south China.
Medical oncology (Northwood, London, England) 2013 Jun 30 (2): 521.
Huang Feng-mao, Chen Han-chun, Khan Md Asaduzzaman, Yang Fu-lan, Wan Xin-xing, Xu Ai-hua, Ou-yang Fang-dan, Zhang Dian-zhe
| Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer.
BMC cancer 2012 Dec 12 (1): 1.
Suzumura T, Kimura T, Kudoh S, Umekawa K, Nagata M, Matsuura K, Tanaka H, Mitsuoka S, Yoshimura N, Kira Y, Nakai T, Hirata K
| [Relationship between the genetic polymorphisms of phase I and II drug-metabolizing enzymes, as well as the outcome of chemotherapy in advanced non-small cell lung cancer].
Zhongguo fei ai za zhi = Chinese journal of lung cancer 2011 Nov 14 (11): 858-64.
Li Weiying, Yue Wentao, Yang Xuehui, Zhang Chunyan, Wang Y
| [CYP2D6*10 polymorphisms and lung cancer susceptibility].
Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 2008 Oct 30 (5): 564-8.
Yan Zhen, Wu Yi-Ming, Wu Yong-J
| A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers.
Carcinogenesis 2008 Jun 29 (6): 1164-9.
Zienolddiny Shanbeh, Campa Daniele, Lind Helge, Ryberg David, Skaug Vidar, Stangeland Lodve B, Canzian Federico, Haugen Aa
| [Combined effects of genetic polymorphisms in cytochrome P450s and GSTM1 on lung cancer susceptibility].
Zhonghua yi xue za zhi 2007 Nov 87 (43): 3064-8.
Gu Yan-Fei, Zhang Zong-De, Zhang Shu-Cai, Zheng Su-Hua, Jia Hong-Yan, Gu Shu-Xia
| CYP450 polymorphisms predict clinic outcomes to vinorelbine-based chemotherapy in patients with non-small-cell lung cancer.
Acta oncologica (Stockholm, Sweden) 2007 46 (3): 361-6.
Pan Ji-Hong, Han Jin-Xiang, Wu Jian-Mei, Sheng Li-Jun, Huang Hai-N
| Tandem repeat polymorphism of the CYP2E1 gene: an association study with esophageal cancer and lung cancer.
Alcoholism, clinical and experimental research 2002 Aug 26 (8 Suppl): 15S-19S.
Itoga Sakae, Nomura Fumio, Makino Yasuhiko, Tomonaga Takeshi, Shimada Hideaki, Ochiai Takenori, Iizasa Toshihiko, Baba Masayuki, Fujisawa Takehiko, Harada Sho
| CYP1A1 and CYP2D6 polymorphism and risk of lung cancer in a North Indian population.
Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 0 8 (5): 415-28.
Sobti R C, Sharma S, Joshi A, Jindal S K, Janmeja